Phase 1 Dyslipidemia Clinical Trials
8 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–8 of 8 trials
Recruiting
Phase 1
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4954 in Healthy Adult Participants With or Without Elevated Lipoprotein (a) (Lp[a]) Levels, and Participants With Dyslipidemia
Healthy ParticipantsDyslipidemia
AstraZeneca136 enrolled6 locationsNCT06980428
Recruiting
Phase 1
A Safety and Tolerability Trial Evaluating CTX310 in Participants With Refractory Dyslipidemias
HypercholesterolaemiaMetabolic DiseaseDyslipidemias+7 more
CRISPR Therapeutics AG90 enrolled18 locationsNCT07491172
Recruiting
Phase 1
A Two-arm, Open-label, Single-sequence, Multiple-dose, Cross-over Study to Evaluate the Pharmacokinetic Interaction and the Safety of UIC202502 and UIC202505 in Healthy Adult Volunteers
Dyslipidemia
Korea United Pharm. Inc.50 enrolled1 locationNCT07162441
Recruiting
Phase 1Phase 2
Integrated Traditional Chinese Medicine Day Care Program for Metabolic Syndrome
Diabetes MellitusObesityMetabolic Syndrome+1 more
Chang Gung Memorial Hospital200 enrolled1 locationNCT06703788
Recruiting
Phase 1
A Study on the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RS-C1001 Tablets in Chinese Healthy Subjects
Dyslipidemia
Peking University First Hospital72 enrolled1 locationNCT06669429
Recruiting
Phase 1
To Evaluate the Safety and Pharmacokinetic Interaction Between HODO-22251 and HODO-22252 in Healthy Adults
Type 2 DiabetesDyslipidemias
Hyundai Pharm56 enrolled1 locationNCT06578676
Recruiting
Phase 1
A Safety and Tolerability Study Evaluating CTX310 in Subjects With Refractory Dyslipidemias
Refractory Dyslipidemias
CRISPR Therapeutics AG24 enrolled1 locationACTRN12623000809639
Completed
Phase 1
A Phase 1 single ascending study in healthy Caucasian and Japanese Adult subjects to evaluate the Safety, Tolerability, and Pharmacokinetics of CSL346.
HyperglycemiaDyslipidemiaAbnormal lipid accumulation
CSL Limited116 enrolled1 locationACTRN12617001554358